AbbVie reported a 17% increase in its stock price during June 2026. The company secured expanded European Union approval for MAVIRET to treat acute and pediatric Hepatitis C. Both the EU and the FDA also approved SKYRIZI for pediatric psoriasis patients.
These approvals expand the addressable markets for AbbVie’s immunology and virology portfolios. To further strengthen its pipeline, the company announced the strategic acquisition of Apogee Therapeutics.
These developments support AbbVie's strategy to diversify revenue streams. The company aims to mitigate the impact of sales erosion from its former blockbuster drug, HUMIRA.